Macular Degeneration clinical trials at UC Davis
3 research studies open to eligible people

  • A Study of Age-Related Macular Degeneration (vision loss) and Reticular Pseudodrusen (yellow pattern in the vision part of eye)

    open to eligible people ages 55 years and up

    Objective: To learn more about AMD. Eligibility: People ages 55 and older with any of the following: AMD or changes in the retina that put them at risk for AMD RPD Healthy eyes Design: Participants will be screened with: Eye exam: The pupil will be dilated with eye drops. Eye pressure and movements will be checked. Pictures will be taken of the inside of the eye. Reading an eye chart. Optical coherence tomography (OCT): The eyes are dilated. A machine measures the thickness of the retina. Participants will have a first visit that includes: Repeat of screening procedures Medical history Physical exam Questions about vision and general health Dark adapted fundus perimetry: Participants sit in the dark for 40 minutes. Then they sit at a machine that shines lights in the eyes. Dark adaption testing: Participants sit in the dark for 45 minutes. The pupils are dilated. They push a button when they see light in a machine for up to 1 hour. Participants will have annual visits for up to 5 years to repeat the tests in the first visit. Participant data may be shared for other research. ...

    Bethesda, Maryland

  • A Study of Experimental Sunitinib Malate (GB-102) Compared to Aflibercept For Wet Age-Related Macular Degeneration

    open to eligible people ages 50 years and up

    Phase 2b, multicenter, visual examiner-masked, randomized active-controlled, parallel-arm design study to evaluate the safety and duration of repeated IVT injections of 3 dose levels of GB‑102 compared with aflibercept.

    Sacramento, California and other locations

  • A Study to Evaluate the Efficacy and Safety of Faricimab in Participants With Neovascular Age-Related Macular Degeneration (TEN...

    open to eligible people ages 50 years and up

    This study will evaluate the efficacy, safety, durability, and pharmacokinetics of faricimab administered at intervals as specified in the protocol, compared with aflibercept once every 8 weeks (Q8W), in participants with neovascular age-related macular degeneration (nAMD). The global enrollment phase has closed, but participants are still being recruited only at sites in Japan.

    Sacramento, California and other locations

Last updated: